TY - JOUR
T1 - A hepatitis C elimination model in healthcare for the homeless organization
T2 - A novel reflexive laboratory algorithm and equity assessment
AU - Seaman, A.
AU - King, C. A.
AU - Kaser, T.
AU - Geduldig, A.
AU - Ronan, W.
AU - Cook, R.
AU - Chan, B.
AU - Levander, X. A.
AU - Priest, K. C.
AU - Korthuis, P. T.
N1 - Funding Information:
Andrew Seaman has received investigator-initiated research funding from Merck & Co Pharmaceuticals unrelated to the content of this research. The authors have no financial relationship with Labcorp or other financial stake in the creation of the laboratory algorithm. All other authors report no financial conflicts of interest. Dr. Korthuis serves as principal investigator for NIH-funded studies that accept donated study medications from Alkermes (extended-release naltrexone) and Indivior (buprenorphine).
Funding Information:
Abuse of the National Institutes of Health under Award Number F30DA052972, and an OHSU Addiction Medicine Seed Grant. Dr. Priest receives research support from National Institute on Drug Abuse under Grant [ F30 DA044700 ]. Dr. Korthuis’ time was supported by grants from the National Institute on Drug Abuse [ UG1DA015815, UH3DA044831 ].
Funding Information:
Dr. Seaman was supported by Central City Concern and the Gilead Sciences' FOCUS program, which provided funding for HIV, HCV, and HBV screening and linkage to the first appointment. Caroline King was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Award Number TL1TR002371, the National Institute on Drug, Abuse of the National Institutes of Health under Award Number F30DA052972, and an OHSU Addiction Medicine Seed Grant. Dr. Priest receives research support from National Institute on Drug Abuse under Grant [F30 DA044700]. Dr. Korthuis? time was supported by grants from the National Institute on Drug Abuse [UG1DA015815, UH3DA044831]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or FOCUS foundation. The authors would like to acknowledge the people living with homelessness, addiction, and hepatitis C who worked together with us as partners to develop these programs. Their input was instrumental to the development of this program and evaluation of its effects. We also recognize the dedication and leadership of Central City Concern in addressing the hepatitis C epidemic in Portland.
Funding Information:
Dr. Seaman was supported by Central City Concern and the Gilead FOCUS foundation. Caroline King was supported by the National Center for Advancing Translational Sciences, National Institutes of Health , through Grant Award Number TL1TR002371 , the National Institute on Drug
Publisher Copyright:
© 2021
PY - 2021/10
Y1 - 2021/10
N2 - Background: Reaching World Health Organization hepatitis C (HCV) elimination targets requires diagnosis and treatment of people who use drugs (PWUD) with direct acting antivirals (DAAs). PWUD experience challenges engaging in HCV treatment, including needing multiple provider and laboratory appointments. Women, minoritized racial communities, and homeless individuals are less likely to complete treatment. Methods: We implemented a streamlined opt-out HCV screening and linkage-to-care program in two healthcare for the homeless clinics and a medically supported withdrawal center. Front-line staff initiated a single-order reflex laboratory bundle combining screening, confirmation, and pre-treatment laboratory evaluation from a single blood draw. Multinomial logistic regression models identified characteristics influencing movement through each stage of the HCV treatment cascade. Multiple logistic regression models identified patient characteristics associated with HCV care cascade progression and Cox proportional hazards models assessed time to initiation of DAAs. Results: Of 11,035 clients engaged in services between May 2017 and March 2020, 3,607 (32.7%) were screened. Of those screened, 1,020 (28.3%) were HCV PCR positive. Of those with detectable RNA, 712 (69.8%) initiated treatment and 670 (94.1%) completed treatment. Of those initiating treatment, 407 (57.2%) achieved SVR12. There were eight treatment failures and six reinfections. In the unadjusted model, the bundle intervention was associated with increased care cascade progression, and in the survival analysis, decreased time to initiation; these differences were attenuated in the adjusted model. Women were less likely to complete treatment and SVR12 labs than men. Homelessness increased likelihood of screening and diagnosis but was negatively associated with completing SVR12 labs. Presence of opioid and stimulant use disorder diagnoses predicted increased care cascade progression. Conclusions: The laboratory bundle and referral pathways improved treatment initiation, time to initiation, and movement across the cascade. Despite overall population improvements, women and homeless individuals experienced important gaps across the HCV care cascade.
AB - Background: Reaching World Health Organization hepatitis C (HCV) elimination targets requires diagnosis and treatment of people who use drugs (PWUD) with direct acting antivirals (DAAs). PWUD experience challenges engaging in HCV treatment, including needing multiple provider and laboratory appointments. Women, minoritized racial communities, and homeless individuals are less likely to complete treatment. Methods: We implemented a streamlined opt-out HCV screening and linkage-to-care program in two healthcare for the homeless clinics and a medically supported withdrawal center. Front-line staff initiated a single-order reflex laboratory bundle combining screening, confirmation, and pre-treatment laboratory evaluation from a single blood draw. Multinomial logistic regression models identified characteristics influencing movement through each stage of the HCV treatment cascade. Multiple logistic regression models identified patient characteristics associated with HCV care cascade progression and Cox proportional hazards models assessed time to initiation of DAAs. Results: Of 11,035 clients engaged in services between May 2017 and March 2020, 3,607 (32.7%) were screened. Of those screened, 1,020 (28.3%) were HCV PCR positive. Of those with detectable RNA, 712 (69.8%) initiated treatment and 670 (94.1%) completed treatment. Of those initiating treatment, 407 (57.2%) achieved SVR12. There were eight treatment failures and six reinfections. In the unadjusted model, the bundle intervention was associated with increased care cascade progression, and in the survival analysis, decreased time to initiation; these differences were attenuated in the adjusted model. Women were less likely to complete treatment and SVR12 labs than men. Homelessness increased likelihood of screening and diagnosis but was negatively associated with completing SVR12 labs. Presence of opioid and stimulant use disorder diagnoses predicted increased care cascade progression. Conclusions: The laboratory bundle and referral pathways improved treatment initiation, time to initiation, and movement across the cascade. Despite overall population improvements, women and homeless individuals experienced important gaps across the HCV care cascade.
KW - Gender
KW - HCV Elimination
KW - Hepatitis C
KW - People Who Inject Drugs
KW - People experiencing homelessness
KW - Race
UR - http://www.scopus.com/inward/record.url?scp=85111260747&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111260747&partnerID=8YFLogxK
U2 - 10.1016/j.drugpo.2021.103359
DO - 10.1016/j.drugpo.2021.103359
M3 - Article
C2 - 34325969
AN - SCOPUS:85111260747
SN - 0955-3959
VL - 96
JO - International Journal of Drug Policy
JF - International Journal of Drug Policy
M1 - 103359
ER -